Smith & Nephew is a multinational medical technology company founded in 1856 that has evolved from a small pharmacy in Hull into a global enterprise operating in more than 100 countries. The company employs over 18,000 people and serves millions of patients annually, focused on the repair, regeneration, and replacement of soft and hard tissue.
The company operates across three main business units spanning orthopaedics, sports medicine, advanced wound management, and robotics-assisted surgery. Its product portfolio includes the PICO negative pressure wound therapy device for wound management, the CORI Surgical System for robotics-assisted procedures, and the REGENETEN Bioinductive Implant for tissue regeneration. These solutions address challenging clinical needs across diverse healthcare systems globally.
Smith & Nephew is listed on both the London Stock Exchange (as a FTSE 100 constituent) and the New York Stock Exchange, reflecting its substantial scale and international reach. The company's mission centres on restoring people's bodies and self-belief through technology that expands the possibilities of living.
